Blood Screening Market Size, Share, Growth Analysis, By Product Type (Reagents & Kits, Instruments), By Technology (Nucleic Acid Test (NAT), Rapid Tests), By End User (Hospitals & Clinics, Diagnostic Centers), By Region - Industry Forecast 2024-2031

Global Blood Screening Market size was valued at USD 3.04 Billion in 2022 and is poised to grow from USD 3.30 Billion in 2023 to USD 6.33 Billion by 2031, at a CAGR of 8.50% during the forecast period (2024-2031). 

The competitive landscape of the blood screening market includes information by competitor. The company's financials, revenue generated, market potential, investment in R&D, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width Details like depth, breadth, and application dominance are also presented. The data presented here only refers to blood screening as a market emphasis for the companies. 'Abbott Laboratories (USA) ', 'Becton, Dickinson and Company (USA) ', 'Bio-Rad Laboratories, Inc. (USA) ', 'bioMérieux SA (France) ', 'F. Hoffmann-La Roche Ltd. (Switzerland) ', 'Grifols, S.A. (Spain) ', 'Hologic, Inc. (USA) ', 'Immucor, Inc. (USA) ', 'Meridian Bioscience, Inc. (USA) ', 'Ortho Clinical Diagnostics (USA) ', 'Quotient Limited (UK) ', 'Siemens Healthineers AG (Germany) ', 'Sysmex Corporation (Japan) ', 'Thermo Fisher Scientific Inc. (USA) ', 'Danaher Corporation (USA) ', 'Grifols Diagnostic Solutions Inc. (USA) ', 'Haemonetics Corporation (USA) ', 'Luminex Corporation (USA) ', 'Natera, Inc. (USA) ', 'Novartis International AG (Switzerland) ', 'PerkinElmer, Inc. (USA) ', 'Promega Corporation (USA) '

There is a growing awareness among healthcare professionals and patients about the risks associated with blood transfusions, such as the transmission of infectious diseases. This is leading to an increased demand for blood screening products that can ensure the safety of blood and blood products.

The demand for plasma-derived products, such as immunoglobulins and clotting factors, is growing, and this is driving the demand for blood screening products that can ensure the safety of these products. This trend is expected to continue as the use of plasma-derived products expands into new therapeutic areas.

A growing prevalence of renal, heart, and bacterial diseases in nations like India and China is predicted to cause the North America market to represent the greatest revenue share in the global market during the projection period. In India, chronic kidney disease affects more than 7.8 million people. In addition to these factors, the market revenue growth is being fueled by increased government and corporate efforts to increase public knowledge and confidence. A rise in cardiovascular diseases and changes in lifestyle are two other elements influencing the market's revenue growth. The largest population of diabetic patients worldwide, at over 141 million, is found in China.